These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 8609068

  • 1. Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models.
    Watanabe T, Naito M, Oh-hara T, Itoh Y, Cohen D, Tsuruo T.
    Jpn J Cancer Res; 1996 Feb; 87(2):184-93. PubMed ID: 8609068
    [Abstract] [Full Text] [Related]

  • 2. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.
    Boesch D, Gavériaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F.
    Cancer Res; 1991 Aug 15; 51(16):4226-33. PubMed ID: 1678313
    [Abstract] [Full Text] [Related]

  • 3. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo.
    Watanabe T, Tsuge H, Oh-Hara T, Naito M, Tsuruo T.
    Acta Oncol; 1995 Aug 15; 34(2):235-41. PubMed ID: 7718262
    [Abstract] [Full Text] [Related]

  • 4. Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models.
    Watanabe T, Nakayama Y, Naito M, Oh-hara T, Itoh Y, Tsuruo T.
    Anticancer Drugs; 1996 Nov 15; 7(8):825-32. PubMed ID: 8991185
    [Abstract] [Full Text] [Related]

  • 5. Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies.
    Watanabe T, Naito M, Kokubu N, Tsuruo T.
    J Natl Cancer Inst; 1997 Apr 02; 89(7):512-8. PubMed ID: 9086008
    [Abstract] [Full Text] [Related]

  • 6. Reversal of multidrug resistance by a novel quinoline derivative, MS-209.
    Sato W, Fukazawa N, Nakanishi O, Baba M, Suzuki T, Yano O, Naito M, Tsuruo T.
    Cancer Chemother Pharmacol; 1995 Apr 02; 35(4):271-7. PubMed ID: 7828268
    [Abstract] [Full Text] [Related]

  • 7. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
    Krishna R, Mayer LD.
    Cancer Res; 1997 Dec 01; 57(23):5246-53. PubMed ID: 9393743
    [Abstract] [Full Text] [Related]

  • 8. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
    Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G.
    Cancer Chemother Pharmacol; 1997 Dec 01; 40 Suppl():S13-9. PubMed ID: 9272128
    [Abstract] [Full Text] [Related]

  • 9. A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells.
    Nokihara H, Yano S, Nishioka Y, Hanibuchi M, Higasida T, Tsuruo T, Sone S.
    Jpn J Cancer Res; 2001 Jul 01; 92(7):785-92. PubMed ID: 11473730
    [Abstract] [Full Text] [Related]

  • 10. SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance.
    Loor F, Boesch D, Gavériaux C, Jachez B, Pourtier-Manzanedo A, Emmer G.
    Br J Cancer; 1992 Jan 01; 65(1):11-8. PubMed ID: 1346365
    [Abstract] [Full Text] [Related]

  • 11. Reversal of multidrug resistance by an immunosuppressive agent FK-506.
    Naito M, Oh-hara T, Yamazaki A, Danki T, Tsuruo T.
    Cancer Chemother Pharmacol; 1992 Jan 01; 29(3):195-200. PubMed ID: 1370765
    [Abstract] [Full Text] [Related]

  • 12. Modulator activity of PSC 833 and cyclosporin-A in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells.
    Lopes EC, Scolnik M, Alvarez E, Hajos SE.
    Leuk Res; 2001 Jan 01; 25(1):85-93. PubMed ID: 11137565
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic efficacy of combination of antitumor agent with AHC-52 against multidrug-resistant cells in the intravenously inoculated P388 leukemia model.
    Shinoda H, Ebisu H, Mitsuhashi J, Inaba M, Tsuruo T.
    Cancer Chemother Pharmacol; 1992 Jan 01; 30(5):335-40. PubMed ID: 1505070
    [Abstract] [Full Text] [Related]

  • 14. Reversal by two dihydropyridine compounds of resistance to multiple anticancer agents in mouse P388 leukemia in vivo and in vitro.
    Kiue A, Sano T, Naito A, Inada H, Suzuki K, Okumura M, Kikuchi J, Sato S, Takano H, Kohno K.
    Jpn J Cancer Res; 1990 Oct 01; 81(10):1057-64. PubMed ID: 1977728
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
    Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon MH, Jan M, Burbridge M, Visalli M, Bisagni E, Pierré A, Atassi G.
    Cancer Chemother Pharmacol; 1996 Oct 01; 38(6):513-21. PubMed ID: 8823492
    [Abstract] [Full Text] [Related]

  • 18. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity.
    Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA, Hiestand PC.
    Int J Cancer; 1992 May 28; 51(3):433-8. PubMed ID: 1534319
    [Abstract] [Full Text] [Related]

  • 19. Reversal of multidrug resistance by novel nitrophenyl pyrones, SNF4435C and D.
    Kurosawa K, Takahashi K, Tsuda E, Tomida A, Tsuruo T.
    Jpn J Cancer Res; 2001 Nov 28; 92(11):1235-41. PubMed ID: 11714449
    [Abstract] [Full Text] [Related]

  • 20. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines.
    Nakanishi O, Baba M, Saito A, Yamashita T, Sato W, Abe H, Fukazawa N, Suzuki T, Sato S, Naito M, Tsuruo T.
    Oncol Res; 1997 Nov 28; 9(2):61-9. PubMed ID: 9167187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.